Quest Diagnostics Incorporated (DGX)

FairStock Score: 53/100 — MIXED

Key Financials

Strengths

• Essential healthcare service with recurring revenue model and low cyclicality (Beta: 0.63)
• Market-leading position with 46,000 employees and established physician/hospital relationships
• Strong free cash flow generation of $1.0B demonstrates operational efficiency
• Reasonable profit margins at 8.73% in latest quarter with stable revenue base of $2.8B
• Defensive characteristics with steady demand regardless of economic cycles

Concerns

• Extreme valuation disconnect: Stock at $201.58 vs Graham Number of $56.87 (254% overvalued)
• Deteriorating financial quality with Piotroski F-Score of only 4/9 indicating negative trends
• Exceptionally high EV/EBITDA of 52.75 and low ROCE of 6.20% signal poor capital efficiency
• Elevated leverage with D/E ratio of 0.90, limiting financial flexibility and dividend capacity

AI Analysis

Quest Diagnostics presents a paradox that troubles me. On one hand, we have a business with genuine competitive advantages—46,000 employees, established relationships with physicians and hospitals, and a recurring revenue model from essential diagnostic services. The company generated $1.0 billion in free cash flow last quarter, which is respectable. However, the valuation metrics scream overvaluation to my sensibilities. At $201.58 per share with a Graham Number of just $56.87, we're looking at a staggering 254% margin of safety deficit. This is not a margin of safety; it's a margin of danger. The P/E of 22.32 is reasonable on the surface, but paired with an EV/EBITDA of 52.75—extraordinarily high for a mature diagnostic services company—I see excessive expectations baked into the price. The ROE of 14.75% is acceptable but not exceptional for a company demanding such premium valuation. Most troubling is the weak Piotroski F-Score of 4/9, suggesting deteriorating financial quality. The ROCE of 6.20% is concerning; capital isn't being deployed efficiently. While diagnostics will always be needed, I cannot justify paying $201 for a dollar of earnings when the intrinsic value signals caution. This is a pass at current prices, despite the business quality.

Bull Case

Quest operates in an essential healthcare segment with aging demographics driving higher diagnostic volumes. Strong free cash flow generation of $1.0B annually provides runway for shareholder returns and strategic acquisitions. The company's diversified brand portfolio and established moat could support steady mid-single digit growth and margin expansion as operational leverage improves.

Bear Case

Deteriorating Piotroski F-Score and weak ROCE suggest the business is losing competitive edge despite its market position. Aggressive valuation leaves no margin of safety, and any disappointment in growth could trigger significant downside. Rising healthcare cost pressures and competitive pressures from larger healthcare conglomerates could compress margins further.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer